This report analyzes the worldwide markets for Respiratory Drugs in US$ Million. The major product segments analyzed are Asthma, Allergic Rhinitis, and COPD (Chronic Obstructive Pulmonary Disease). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 69 companies including many key and niche players worldwide such as Accentia Biopharmaceuticals, Inc., Aerogen, Inc., Aerovance, Inc., airPharma, AstraZeneca, Aventis Pharma Limited, Bespak, Boehringer Ingelheim Pharmaceuticals, Inc., Cadila Pharmaceuticals, Dr. Reddy's Laboratories, EvoGenix, GlaxoSmithKline, GlaxoSmithKline Pharmaceuticals Ltd., Inyx, Inc., The Merck Generics Group, Novartis AG, Pfizer, Inc., Ranbaxy Laboratories Limited, Respironics, Inc., Sandoz International GmbH, and Schering-Plough Corp. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

RESPIRATORY DRUGS								MCP-1577
A GLOBAL STRATEGIC BUSINESS REPORT


                                             CONTENTS


  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS


 II. EXECUTIVE SUMMARY

  1.  Market Overview                                                   II-1
      Respiratory Diseases - Common and Serious                         II-1
      Rhinoviruses - Root Cause of Major Respiratory  Diseases          II-1
      Leading Asthmatic Drugs and their Patent Expiries                 II-2
      Antihistamine or Allergic Rhinitis Market                         II-2
      Leading Anti-Allergy Drugs and Patent Expiry Years                II-3
      Current and Future Analysis                                       II-3
       Regional Perspective                                             II-3
       Product Segment Perspective                                      II-3

  2. Common Respiratory Diseases - Overview                             II-4
      Influenza                                                         II-4
      Asthma                                                            II-4
       Factors Promoting Asthma                                         II-5
       Treatment                                                        II-5
      Respiratory Distress Syndrome (RDS)                               II-5
       Symptoms                                                         II-6
       Complications Related to RDS                                     II-6
       Analysis of RDS                                                  II-6
       Alternative Methods for the Treatment of RDS                     II-7
       Preventive Measures                                              II-7
      Chronic Obstructive Pulmonary Disease                             II-8
       Characteristics and Symptoms of COPD                             II-8
        Risks Associated with COPD                                      II-8
      Bronchitis                                                        II-9
      Respiratory Syncytial Virus (RSV)                                 II-9

  3. Treatment of Respiratory Diseases - An Overview                    II-10
      Respiratory Therapy with Information Technology                   II-10
      Antiviral Drugs for Controlling Influenza and RSV  Infections     II-10
      Pulmonary Drug Delivery                                           II-10
       Why are Lungs Considered a Good Alternative?                     II-10
      COPD - Taking a Toll on Human Lives                               II-11
      Upper Respiratory Tract Infections (URIs)                         II-11
      Respiratory Failure Management                                    II-11
       CPAP: Non-Invasive Respiration                                   II-12
       Face Masks: Carriers of Oxygen Therapy                           II-12
       Endotracheal Intubation and Ventilatory Support                  II-12
        Endotracheal Intubation Turns Perilous                          II-13
        Ventilator Strategy                                             II-13
         Methods of Ventilation                                         II-14
          Weaning from the Ventilator                                   II-15
       Respiratory Support: A Broader Perspective                       II-15
        Humidification                                                  II-15
        Posture                                                         II-15
        Physiotherapy                                                   II-15
        Pharmacological Adjuncts                                        II-15
        Sedation                                                        II-16
      New Drugs, Treatments Ease Life of Patients with  Respiratory
       Problems                                                         II-16
       Progesterone                                                     II-16
       Partial Liquid Ventilation                                       II-17
       Heliox                                                           II-17
       High-level PREP                                                  II-18
      Respiratory Failure                                               II-18
       Types of Respiratory Failure                                     II-19
       Factors Leading to Respiratory Failure                           II-19
        Blockage of air passage                                         II-19
        Drug abuse or alcohol addiction                                 II-19
        Obesity                                                         II-19
        Muscle weakness                                                 II-19
        Lung disorders and diseases                                     II-19
        Abnormalities in Chest Walls                                    II-19
        Cellular Disorders                                              II-19
       Treatment for Respiratory Failure                                II-20
       Role of Health Care Teams                                        II-20
       Long-Term Consequences of Respiratory Failures                   II-21
       Preventive Measures                                              II-21
        Measures to Prevent the Recurrence of Respiratory  Diseases     II-21
       Telithromycin: Treatment for Respiratory Disorders               II-21
        Consequences of Telithromycin                                   II-22

  4.  Recent Industry Activity                                          II-23
      Arcadia Resources, Inc Acquires Remedy Therapeutics,  L.L.C       II-23
      Sirna Forms Alliance with GlaxoSmithKline                         II-23
      Pharmaxis Ltd and Nigaard Pharma Enters into  Distribution
       Agreement                                                        II-23
      Teva Regains Leadership Position through Ivax  Acquisition        II-23
      AstraZeneca Submits Symbicort for US FDA Approval                 II-24
      Ranbaxy Laboratories Receives FDA Approval                        II-24
      Innovata Inks Development Agreement for Duohaler                  II-24
      Novartis Obtains License from Arrow Therapeutics for  A60444
       Molecule Inhibitor                                               II-24
      Arakis Ltd and Vectura Group plc Initiate Phase IIb Clinical
       Trial of NVA237                                                  II-25
      Schering-Plough Receives FDA Approval for Asmanex                 II-25
      Isis Pharmaceuticals Develops ISIS 369645                         II-25
      Inyx Acquires Celltech Manufacturing Services from  UCB           II-25
      Ashton Pharmaceuticals Partners with Innovata and  Merck          II-25
      King Pharmaceuticals Collaborates with Inyx                       II-26
      Inyx Pharma Ltd. Bags a Contract from Generics                    II-26
      Alnylam Pharmaceuticals Initiates Phase I Trials on  ALN-RSV01    II-27
      MAP and Elan Extend their Agreement for Developing  Advanced
       Version of Asthma Drug                                           II-27
      Accentia Enters into Licensing Agreement with  Collegium          II-27
      Novartis Inks Agreement with Arakis and Vectura                   II-28
      Pfizer and Rigel Sign Collaborative Agreement                     II-28
      NicOx Enters into Developing and Licensing Agreement  with
       Topigen                                                          II-29
      Merck to Strike a Licensing Deal with Innovata for  Developing
       Respiratory Medicines                                            II-29
      Lannett Receives Approval from FDA for the Distribution  of
       Terbutaline Sulfate Tablets                                      II-30
      GlaxoSmithKline Licenses Inhaled Respiratory Therapy  from
       Theravance                                                       II-30
      Novartis' Sandoz Completes Acquisition of Hexal AG                II-31
      Sandoz Acquires Eon Labs                                          II-31
      SkyePharma, PLC Enters into License Agreement with
       GlaxoSmithKline                                                  II-31
      Kos Pharmaceuticals Signs Agreement with Aventis  Pharmaceuticals II-31
      US FDA Approves New Antibiotic, Ketek                             II-31
      Zambon Terminates Single-Agent Inhaler Project                    II-32
      Boehringer Ingelheim Pharmaceuticals Obtains FDA  Approval for
       Atrovent HFA                                                     II-32
      Ranbaxy Receives FDA Approval for Loratadine  and
       Pseudoephedrine Sulfate Tablets                                  II-32
      Lincoln Pharmaceuticals Limited Introduces Gatilink, an
       Antibiotic                                                       II-32
      GlaxoSmithKline Forms Alliance with Theravance                    II-33
      Etiologics Acquires Bayer's Pre-clinical Respiratory  Research
       Group                                                            II-33
      IVAX Pharmaceutical Signs Pan-European Agreement  with 3M         II-33
      GlaxoSmithKline Inks Agreement with Theravance                    II-33
      Cadila Pharmaceuticals Ltd Launches Montelast for  Asthma         II-33
      Alpharma Unveils Generic Loratadine Syrup                         II-33
      Dr. Reddy's Laboratories Launches Brancho-Vaxom                   II-33

  5.  Focus on Select Players                                           II-34
      Accentia Biopharmaceuticals, Inc. (US)                            II-34
      Aerogen, Inc. (US)                                                II-34
      Aerovance, Inc (US)                                               II-34
      airPharma (US)                                                    II-34
      AstraZeneca (UK)                                                  II-35
      Aventis Pharma Limited (India)                                    II-35
      Bespak (UK)                                                       II-35
      Boehringer Ingelheim Pharmaceuticals, Inc (Germany)               II-35
      Cadila Pharmaceuticals (India)                                    II-35
      Dr. Reddy's Laboratories (India)                                  II-36
      EvoGenix (Australia)                                              II-36
      GlaxoSmithKline (US)                                              II-37
      GlaxoSmithKline Pharmaceuticals Ltd. (India)                      II-37
      Inyx, Inc. (US)                                                   II-37
      The Merck Generics Group (Germany)                                II-37
      Novartis AG (Switzerland)                                         II-38
      Pfizer, Inc. (US)                                                 II-38
      Ranbaxy Laboratories Limited (India)                              II-39
      Respironics, Inc (US)                                             II-40
      Sandoz International GmbH (Germany)                               II-40
      Schering-Plough Corp (US)                                         II-41

  6.  Global Market Perspective                                         II-42
      Table 1: Recent Past, Current and Future Analysis for
      Respiratory Drugs by Geographic Region - US, Canada,  Japan,
      Europe and Rest of World Markets Independently Analyzed by
      Annual Sales in US$ Million for the  Years 2000 through 2010
      (includes corresponding  Graph/Chart)                             II-42

      Table 2: World 10-Year Perspective for Respiratory Drugs by
      Geographic Region - Percentage Breakdown of Dollar  Sales for
      US, Canada, Japan, Europe and Rest of World  Markets for the
      Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)    II-42

      Table 3: World Recent Past, Current and Future Analysis  for
      Asthma Drugs by Geographic Region - US, Canada,  Japan, Europe
      and Rest of World Markets Independently Analyzed by Annual
      Sales in US$ Million for the  Years 2000 through 2010
      (includes corresponding  Graph/Chart)                             II-43

      Table 4: World 10-Year Perspective for Asthma Drugs by
      Geographic Region - Percentage Breakdown of Dollar  Sales for
      US, Canada, Japan, Europe and Rest of World  Markets for the
      Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)    II-43

      Table 5: World Recent Past, Current and Future Analysis  for
      Allergic Rhinitis Drugs by Geographic Region - US,  Canada,
      Japan, Europe and Rest of World Markets Independently Analyzed
      by Annual Sales in US$ Million  for the Years 2000 through
      2010 (includes  corresponding Graph/Chart)                        II-44

      Table 6: World 10-Year Perspective for Allergic Rhinitis
      Drugs by Geographic Region - Percentage Breakdown of  Dollar
      Sales for US, Canada, Japan, Europe and  Rest of World Markets
      for the Years 2000, 2006  and 2010 (includes corresponding
      Graph/Chart)                                                      II-44

      Table 7: World Recent Past, Current and Future Analysis  for
      Chronic Obstructive Pulmonary Disease (COPD) Drugs  by
      Geographic Region - US, Canada, Japan, Europe and  Rest of
      World Markets Independently Analyzed by Annual  Sales in US$
      Million for the Years 2000 through 2010  (includes
      corresponding Graph/Chart)                                        II-45

      Table 8: World 10-Year Perspective for Chronic Obstructive
      Pulmonary Disease (COPD) Drugs by Geographic Region -
      Percentage Breakdown of Dollar Sales for US, Canada,  Japan,
      Europe and Rest of World Markets for the  Years 2000, 2006 and
      2010 (includes corresponding Graph/Chart)                         II-45


III. MARKET

  1.  The United States                                                 III-1
      A.Market Analysis                                                 III-1
        Current & Future Analysis                                       III-1
        Market Scenario                                                 III-1
         Asthma                                                         III-1
         COPD                                                           III-2
        Leading Respiratory Drug Brands                                 III-2
        Strategic Corporate Developments                                III-2
        Focus on Select Players                                         III-8
      B.Market Analytics                                                III-11
        Table 9: US Recent Past, Current and Future Analysis  for
        Respiratory Drugs by Product Segment - Asthma  Drugs,
        Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary
        Disease (COPD) Drugs Independently  Analyzed by Annual Sales
        in US$ Million for the  Years 2000 through 2010 (includes
        corresponding Graph/Chart)                                      III-11

        Table 10: US 10-Year Perspective for Respiratory  Drugs by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Asthma Drugs, Allergic Rhinitis Drugs  and Chronic
        Obstructive Pulmonary Disease (COPD) Drugs for the Years
        2000, 2006 and 2010 (includes corresponding Graph/Chart)        III-11

  2.  Canada                                                            III-12
      Market Analysis                                                   III-12
        Table 11: Canadian Recent Past, Current and Future Analysis
        for Respiratory Drugs by Product Segment - Asthma Drugs,
        Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary
        Disease (COPD) Drugs Independently Analyzed by Annual Sales
        in US$  Million for the Years 2000 through 2010  (includes
        corresponding Graph/Chart)                                      III-12

        Table 12: Canadian 10-Year Perspective for Respiratory Drugs
        by Product Segment - Percentage Breakdown  of Dollar Sales
        for Asthma Drugs, Allergic Rhinitis  Drugs and Chronic
        Obstructive Pulmonary  Disease (COPD) Drugs for the Years
        2000,  2006 and 2010 (includes corresponding  Graph/Chart)      III-13

  3.  Japan                                                             III-14
      Market Analysis                                                   III-14
        Table 13: Japanese Recent Past, Current and Future Analysis
        for Respiratory Drugs by Product Segment - Asthma Drugs,
        Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary
        Disease (COPD) Drugs Independently Analyzed by Annual Sales
        in US$ Million  for the Years 2000 through 2010 (includes
        corresponding Graph/Chart)                                      III-14

        Table 14: Japanese 10-Year Perspective for Respiratory Drugs
        by Product Segment - Percentage Breakdown of Dollar Sales
        for Asthma Drugs, Allergic Rhinitis  Drugs and Chronic
        Obstructive Pulmonary Disease (COPD) Drugs for the Years
        2000, 2006 and 2010  (includes corresponding Graph/Chart)       III-15

  4.  Europe                                                            III-16
      A.Market Analysis                                                 III-16
        Current & Future Analysis                                       III-16
        Strategic Corporate Developments                                III-16
        Focus on Select Players                                         III-20
      B.Market Analytics                                                III-23
        Table 15: European Recent Past, Current and Future Analysis
        for Respiratory Drugs by Product Segment - Asthma Drugs,
        Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary
        Disease (COPD) Drugs Independently Analyzed by Annual Sales
        in US$  Million for the Years 2000 through 2010  (includes
        corresponding Graph/Chart)                                      III-23

        Table 16: European 10-Year Perspective for Respiratory Drugs
        by Product Segment - Percentage Breakdown  of Dollar Sales
        for Asthma Drugs, Allergic Rhinitis  Drugs and Chronic
        Obstructive Pulmonary Disease (COPD) Drugs for the Years
        2000, 2006 and 2010  (includes corresponding Graph/Chart)       III-23

  5.  Rest of World                                                     III-24
      A.Market Analysis                                                 III-24
        Current & Future Analysis                                       III-24
        Strategic Corporate Developments                                III-24
        Focus on Select Players                                         III-25
      B.Market Analytics                                                III-29
        Table 17: Rest of World Recent Past, Current and Future
        Analysis for Respiratory Drugs by Product Segment - Asthma
        Drugs, Allergic Rhinitis Drugs and Chronic Obstructive
        Pulmonary Disease (COPD) Drugs Independently Analyzed by
        Annual Sales in US$  Million for the Years 2000 through 2010
        (includes corresponding Graph/Chart)                            III-29

        Table 18: Rest of World 10-Year Perspective for  Respiratory
        Drugs by Product Segment - Percentage Breakdown of Dollar
        Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic
        Obstructive Pulmonary  Disease (COPD) Drugs for the Years
        2000, 2006  and 2010 (includes corresponding Graph/Chart)       III-29


 IV. COMPETITIVE LANDSCAPE